Read our Recent Headlines


December 8 Biotech Update

Finally, he sector responded well to good news and held those gains. That bodes well heading into ASH (assuming more positive news) but we obviously cannot give all the gains.

The Bitcoin Bubble

Bitcoin is a bubble. Bitcoin is overvalued. There is a lot of hysteria about bitcoin but that is from both those drinking the koolaid as well as those screaming bubble.

December 7 Biotech Update

I thought we would have to wait until ASH to get a good tell on the market but if the sector cannot hold onto gains today, then there is a.

December 6 Biotech Update

The sector and stocks are going to give everyone whiplash. Despite their being some out performers, it seems like every move higher gets smashed later in the day. There are.

December 5 Biotech Update

I was quite wrong about the sector setting up well and it is not immediately clear to me why the sector did so poorly. I want to go through a.

December 4 Biotech Update

The sector is tied to macro but given the macro events (tax bill status and Flynn flipping) it is not surprising to see this. Ultimately, it is more likely that.

December 1 Biotech Update

It looks like the market and sector are going to be tied to the fate of the tax bill (at least that is how it seemed yesterday) and that makes.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!